Bristol Myers Squibb (BMY)

Total return at 5 years: 21.1%/year = 17.5% appreciation + 3.6% dividend. The target price ($129) is ex-dividend; the $14 in dividends collected over 5 years are added separately.

By both methods, the value today (DCF $197 · Multiples $116) exceeds the market price ($58).

Today — with margin of safety: at $58 trades ~50.2% below its value discounted to today (~$116) — the wide discount we require (≥38%, equivalent to a ~15% annual return); the risk is covered by the margin, not the rate.

At 5 years — Muy infravalorado: the target price ($129) plus dividends yield above the required average return (10%) — the business compounds.

The bridge: the return at 5 years comfortably exceeds the risk-free rate (4.5%) — and the discount reaches the required margin of safety.

Educational / informational. Does not constitute investment advice.

The inverse approach: instead of projecting growth to obtain the value, the market price ($58) is taken as given and it solves for what annual owner-earnings growth would need to hold for 5 years for the present value —at the method's rate (4.5%, no-growth terminal)— to equal that price. It is the disconfirmation test: the expectations the price already pays for, contrasted against the method's projection.

The market discounts less growth (-18.6%/year) than we project (7.0%/year) → if the base case holds, there is margin: perception is more pessimistic than the estimated reality.

That growth implies ~$4.7 bn of owner earnings in year 5 (vs ~$18.6 bn of our base case). It recalculates if the DCF assumptions are edited.

Year-by-year projection of the selected scenario. From each year, two versions of the flow are derived: growth FCF (operating flow − total capex, the cash surplus) and maintenance FCF (the owner earnings: what the business yields if it only sustains its capacity). The flow is returned almost in full (dividend + buyback) or redeployed into the operation, so that EV stays roughly flat and multiples compress because the metric grows, not because of cash accumulation. The valuation is done on NOPAT (EV/NOPAT). In edit mode, revenue, margins, capex, and exit multiples can be adjusted.

Year 0 = TTM to 30-Jun-2026 (US$49,186 million of revenue), normalized to an adjusted earnings margin of 27% -between the margin of the most recent quarter (32.4% in Q2'26, with no IPRD charges that quarter) and the average of the last four quarters, which include larger IPRD charges and impairments in the second half of 2025-. Year 1 anchors to the raised guidance in the earnings release of 30-Jul-2026 (8-K, Item 2.02): total revenue US$49,000-50,000 million (+2.7% year over year against the full 2025 fiscal year) and non-GAAP earnings per share US$6.75-7.00, implying an adjusted earnings margin of approximately 28.4% at the guidance midpoint -the source of the model's margin trajectory, using both anchors of the guidance (revenue and earnings per share), not just one-. From year 2 onward, the path assumes a slight deceleration in year 1 (the free Medicaid program for Eliquis and the continuing generic erosion of Revlimid/Sprycel weigh more in the remaining half) followed by a gradual reacceleration toward year 5, as the Growth Portfolio (Opdivo, Reblozyl, Breyanzi, Camzyos, Opdualag) gains weight in the mix and the ever-smaller Legacy Portfolio weighs less on the consolidated figure. The margin expands moderately on the cost savings program (approximately US$2,000 million by the end of 2027) and because the amortization of acquired intangibles keeps receding (US$3,317 million in 2025 against US$8,872 million in 2024, after the full amortization of Revlimid and Pomalyst). The terminal exit multiple (15x) sits in the lower half of the branded pharmaceutical band (14-22x), reflecting that the moat is eroding (Eliquis exclusivity expiries 2026-2028 and Opdivo 2028-2031) despite a return on capital solidly above the 10% bar. No share repurchases (a US$5,000 million authorization went unused in 2025): the surplus flow goes to the dividend and to debt reduction after the leverage from the Karuna, Mirati and RayzeBio acquisitions.

Today's elevated multiple is the price of growth: if the business grows, the entry point cheapens on its own going forward (the metric grows while EV stays roughly flat). The exit multiple at 3 years is higher than the terminal at 5 years —at 3 years there is more growth still ahead—, so the value curve shows whether value creation is concentrated in the early or the later years. The required return is applied to the base scenario.

They are valued separately, with their own rationale, and are not incorporated into the base or the verdict (they are excess return). When assigning them value — in Editmode —, the total with optionalities updates live, without moving the base.

The verdict, the base CAGR, and the margin of safety are always calculated on the base; optionalities do not alter them (with optionalities at $0 they do not move).

Each card fixes a required annual return and answers: if the business is worth $129 in 5 years, what is the maximum that can be paid today to obtain that return? Since it now trades at $58, the margin of safety is how much cheaper the market is than that maximum. The three thresholds: 4% covers inflation (the floor), 10% is the long-term average return, and 15% is the level of a great investment.

With a target price of $129 in 5 years plus $14 of dividends collected (the dividend adds to the return, not to the price) and a required return of 4.5% annually, the maximum to pay today is $116. Against the current market price ($58), the margin of safety is 50.2% (trades below the maximum → there is margin) and the total return at that price would be 21.1% annually.

• Current entry multiple. The stock trades at a high-single-digit adjusted earnings multiple, well below the floor of the branded pharmaceutical band (14-22x) applied to the exit multiple.
• Sensitivity to the exit multiple. The base case uses 15x on normalized adjusted earnings, in the lower half of the band, reflecting the moat's eroding direction despite the solid return on capital.
• Scenario range. The 5-year value ranges between the adverse scenario (faster Eliquis erosion, with no timely Growth Portfolio recomposition) and the favorable one (pipeline delivers additional launches), with the base in between.
• Dividend yield. The current dividend of US$2.52 per share represents a meaningful yield on the market price, with a policy of moderate and consistent growth.
• Comparison with mature pharmaceuticals. Other branded pharmaceuticals of similar quality trade above this stock's implied multiple today, consistent with the market pricing in the patent cliff more severely than the Growth Portfolio's trajectory.
• Margin of safety. The discount against the maximum price that sustains the required 15% annual return is wide in the base case, though it narrows significantly in the adverse scenario.
• Reverse-DCF approach. The growth implied by the current price is modest relative to the Growth Portfolio's actual trajectory, suggesting the price is not paying for demanding expectations.

Each margin over sales, year by year: historical (solid line) → projection (dotted).

• ✓ ROIC exceeds the cost of capital (~10%)
• ✓ CFROIC backs up the ROIC (114%, cash vs. accruals)
• ✓ Healthy balance sheet (low corporate debt)
• ✓ Durable competitive moat (multiple advantages)

• Return on capital. Return on invested capital sits solidly above the 10% bar, calculated on equity plus debt minus cash from the balance sheet.
• Operating cash generation. TTM operating cash flow is US$12,782 million, with healthy cash conversion relative to reported net income.
• Quality of reported earnings. GAAP earnings were negative in 2024 (US$8,948 million) due to a non-recurring US$12,100 million acquired in-process research and development charge tied to Karuna, a distortion that does not reflect the business's operating economics.
• Stock-based compensation. Stock-based compensation expense is only 1.1% of revenue and 4.8% of free cash flow, not material enough to distort the valuation metric.
• Reinvestment runway. The pipeline of more than 45 assets and external collaborations offer a broad reinvestment runway, though with the structurally high failure rate that characterizes the pharmaceutical industry.
• Accounting distortions to watch. Amortization of acquired intangibles and acquired in-process research and development charges generate large year-to-year swings in GAAP earnings that do not reflect the underlying cash flow of the business.
• Capital cycle. Capital keeps entering the industry via acquisitions because the return on a successful product during its exclusivity window is high; this pressures the company to sustain the pipeline with continued licensing and M&A.

Annual levels from the official filing (10-K); the % over each bar is the year-over-year (YoY) growth vs the prior year.

In a branded pharmaceutical the driver is not volume times price for a single product but portfolio composition: how much each franchise weighs and at what rate it grows or declines, weighted by each molecule's exclusivity expiration. Amortization of acquired intangibles is a leading indicator of operating margin: as intangibles from past acquisitions finish amortizing, reported margin expands without any change in the underlying economics of the business.

The % are the annual (year-over-year) growth: each year —historical and projected— vs the prior one; the TTM (trailing 12m) vs the TTM of a year ago, to avoid overlapping windows. The historicals are exact figures from the official filings; the projected years come from the year-by-year model (the intermediate years without their own series are interpolated between the anchors). The projected columns (+1y…+5y) are 12-month windows counted from the TTM close (30-jun-2026): the projection starts from the most recently reported data, not the fiscal year. The projected base is realistic and unbiased — the risk discount is applied at the end, via the required return. The rationale for each metric is in the (i).

• Recent consolidated growth. Revenue practically flat in 2025 (-0.2%), with TTM through June 30, 2026 at +3.1% year over year, reflecting the near-exact offset between the Growth and Legacy Portfolios.
• Raised 2026 guidance. The July 30, 2026 press release raised revenue guidance to US$49,000-50,000 million and non-GAAP earnings per share guidance to US$6.75-7.00, following better-than-expected first-half performance.
• Growth Portfolio. Grew +17% in 2025, led by Breyanzi (+82%), Camzyos (+77%) and Reblozyl (+31%); it already accounts for 54.8% of total revenue.
• Legacy Portfolio. Fell -15% in 2025 from generic erosion of Revlimid (-49%) and Sprycel (-62%); Eliquis, within this portfolio, showed recent strength (guidance raised to +20-25% for 2026).
• Development pipeline. More than 45 unique assets in development, with recent regulatory milestones for Reblozyl, mezigdomide, Camzyos and Opdivo, plus active collaborations with BioNTech, SystImmune and Hengrui.
• Upcoming exclusivity expirations. Eliquis loses regulatory exclusivity between 2026 and 2028 and Opdivo between 2028 and 2031, requiring the pipeline to continuously replace revenue.
• Net selling price. Fell 4% in 2025 due to the Medicare Part D redesign and a mix shift toward higher-discount government channels, a structural headwind on revenue growth.

• Recurrence and predictability. Revenue depends on the duration of each product's exclusivity, not on structurally recurring demand; predictability is high while exclusivity lasts and drops sharply once it is lost.
• Product differentiation. Growth Portfolio products (Opdivo, Reblozyl, Breyanzi, Camzyos) are differentiated therapies with their own clinical evidence, not commoditized while exclusivity lasts.
• Pricing power. Average net selling price fell 4% in 2025 due to the Medicare Part D redesign and a mix shift toward higher-discount channels; the Inflation Reduction Act limits pricing power going forward on selected products.
• Operating leverage. Declining amortization of acquired intangibles frees up operating margin without needing revenue growth, a structural operating leverage distinct from the classic volume-driven kind.
• Behavior in recessions. Demand for innovative medicines for serious diseases is largely insensitive to the economic cycle; the relevant risk is regulatory and patent-related, not macroeconomic.
• Capital entering and exiting the sector. The industry attracts capital consistently via acquisitions (Karuna, Mirati, RayzeBio in this company) because returns on a successful product are high during its exclusivity window.
• Market and relevance in 10 years. The focus therapeutic areas (oncology, hematology, immunology, cardiovascular, neuroscience) have structural long-term demand; the relevant question is whether the pipeline replaces revenue lost to exclusivity expiration.

Not all debt is equal: only the structural needs refinancing; the rest is operational (self-liquidating).

Structural debt is what is exposed to the contraction phase of the cycle; operational debt (leases, matched funding) self-liquidates with the business.

• ✓Leverage (net debt / EBITDA)Net cash $0 bn
• ✓Interest coverage (EBIT / interest)9.9x
• –Liquidity (current ratio)no data
• ✓Cash quality (CFROIC vs ROIC)CFROIC backs 114% of ROIC
• ✓Value creation (ROIC − 10% bar)+15pp
• ✓Malinvestment test (capex vs incremental ROIC)Capex/D&A 0.4x — no over-investment
• !Float / working capitalConsumes cash $0.5 bn (positive WC)
• ✓Dilution (SBC % of revenue + shares)SBC 1.1% of revenue

A traffic-light interpreted by the method (not generic): float (negative WC) adds up, capex is judged by incremental ROIC (malinvestment test), and a lender is not subjected to corporate solvency. The (i) shows the derivation of each number.

• Leverage. Total debt exceeds US$42,000 million following the 2023-2024 acquisitions, although the company already redeemed US$8,700 million early in 2025 and continues reducing the balance.
• Liquidity. Cash and equivalents at the close of the second quarter of 2026 are US$8,722 million, enough to cover short-term debt service and the current dividend.
• Credit rating. S&P downgraded the long-term rating from A+ to A following the December 2023 acquisition announcements, reflecting higher leverage.
• Free cash flow. TTM operating cash flow (US$12,782 million) comfortably covers capex (US$1,342 million) and the dividend (US$5,095 million paid in the period), leaving room for debt reduction.
• Dividend coverage. The dividend is covered by free cash flow with ample margin, with no need to rely on additional debt to sustain it.
• Debt maturities. The early redemption of US$8,700 million in 2025 reduces the short- and medium-term maturity burden, though it generated an accounting loss of US$356 million on the transaction.

Who owns the shares — the alignment and whether there is a controlling shareholder.

• Capital allocation. Prioritizes the dividend and debt reduction over share buybacks, consistent with the stated deleveraging objective after the 2023-2024 acquisitions.
• Acquisition track record. Karuna, Mirati and RayzeBio raised leverage and prompted an S&P credit rating downgrade; the market has not yet validated whether those acquisitions will generate a return on invested capital.
• Alignment and integrity. The earnings release explicitly acknowledges the Legacy Portfolio's erosion rather than downplaying it, and guidance is updated transparently quarter by quarter.
• Governance structure. The chief executive officer also chairs the board, a concentration of roles that reduces the formal separation between management and oversight, although it is common in the industry.

• Accounting loss of US$8,948 million in 2024 (from the US$12,100 million acquired in-process research and development charge for Karuna) that still weighs on perception, even though it is a non-recurring, non-economic charge
• The Eliquis and Revlimid patent cliff dominates the valuation headline even though the Growth Portfolio is already more than half of revenue and growing at a double-digit rate
• Elevated leverage from the Karuna, Mirati and RayzeBio acquisitions, which prompted an S&P credit rating downgrade from A+ to A and generates caution about financial flexibility

No evidence is found that the business is broken: the Growth Portfolio grows at a double-digit rate, guidance was raised in the most recent quarter, and the company prioritizes reducing debt over buying back shares. The discount looks more like an excessively literal reading of the flat consolidated headline and the 2024 accounting loss than a reflection of the business's real trajectory.

The annual return (CAGR at 5 years) in each scenario, with the total period return below — the margin of safety made visual: upside range wide, downside range narrow.

Even in the bear scenario, the return holds at +12%/year (+74% total): the margin of safety protects the downside. The bull (+29%/year, +256% total) exceeds it comfortably — a favorable asymmetry, with a narrow downside range and a wide upside range.

• Eliquis and Opdivo exclusivity expiration. Eliquis loses regulatory exclusivity between 2026 and 2028 and Opdivo between 2028 and 2031; the filing states that sales declines following the loss of exclusivity are typically substantial and rapid.
• Price negotiation under the Inflation Reduction Act. HHS has already set the maximum fair price for Eliquis and Pomalyst, and selected Orencia for negotiation starting in 2028; more products could be added.
• Concentration in few products. Eliquis, Opdivo, Orencia, Reblozyl and Yervoy will represent the majority of revenue, earnings and cash flow in coming years; an adverse event in any of them would have a material impact.
• Acquisition-driven leverage. Additional debt from Karuna, Mirati and RayzeBio reduced financial flexibility and prompted a credit rating downgrade; future transactions could require further leverage.
• Research and development failure rate. Approximately 93% of small molecules entering phase 1 do not reach regulatory approval; the pipeline needs to continuously replace revenue that is lost.
• Pressure on net selling price. Average net selling price fell 4% in 2025 due to the Medicare Part D redesign and a mix shift toward higher-discount channels, a headwind that could deepen.

Each thinker's analytical framework applied to our data.

• Buffett / Graham Quality + margin of safety

  Fails the quality gate: narrow moat, eroding.

• Peter Lynch Growth at a reasonable price (GARP)

  A stalwart growing 7% at a multiple/growth of 1.5 → reasonable for its growth.

• Joel Greenblatt Cheap and high-return (Magic Formula)

  Earnings yield 16% (EBIT/EV) + ROIC 25% → makes the Magic Formula.

• Howard Marks Perception vs reality + cycle

  The price discounts -19% vs our 7%: perception is more pessimistic than reality, with an identified source of the discount.

• Seth Klarman Capital protection (bear scenario)

  Bear-scenario floor +8%/yr, bull-scenario ceiling +26%/yr over 5y and a +50% margin → capital protected, asymmetry in your favor.

• Pat Dorsey Moat strength (Five Rules)

  A narrow moat, eroding; sources: intangibles, efficient scale, switching costs, cost advantage → fails the Five Rules.

• Aswath Damodaran Expectations implied by the price

  Justifying the price requires discounting -19%, within what we project (7%) — the story squares with the numbers.